StockStory Highlights Vertiv as Cash-Rich Buy, Flags UiPath and Surgery Partners as Risky

StockStory··Read original
2▲1 ▼2Impact / 5
Summary · why it matters

StockStory identifies Vertiv as a cash-producing stock worth buying, while labeling UiPath and Surgery Partners as risky investments. Vertiv, formerly part of Emerson Electric, boasts a trailing 12-month free cash flow margin of 21.2%, average organic revenue growth of 23.7% over two years, and a free cash flow margin that increased by 22.4 percentage points over five years. In contrast, UiPath's annual revenue growth of 11.2% over two years and estimated sales growth of 8.2% for the next 12 months raise concerns, while Surgery Partners faces estimated sales growth of just 3.2% and a high net-debt-to-EBITDA ratio of 7×. Vertiv trades at $301.70 per share, UiPath at $11.70, and Surgery Partners at $16.89.

Impact on assets 3

Artificial Intelligence± Mixed · 2 stocks
Uipath Inc
PATH
▼ NegativeCapitalrelevance

StockStory flags UiPath as risky due to low revenue growth and high valuation concerns.

Vertiv Holdings Co
VRT
▲ PositiveCapitalrelevance

StockStory highlights Vertiv as a cash-rich buy with strong free cash flow margin and revenue growth.

Health Care▼ · 1 stocks
Surgery Partners Inc
SGRY
▼ NegativeCapitalrelevance

StockStory flags Surgery Partners as risky due to low sales growth and high net-debt-to-EBITDA ratio.

© 2026 MarketIVNews